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Abstract: Fifty-one parent-offspring pairs with chronic lymphocytic leukemia (CLL) or other lymphoproliferative disorders (nonCLL) 
such as malignant lymphoma, multiple myeloma, or other types of lymphocytic leukemia than CLL were ascertained independently in 
38 families. There were 30 CLL-CLL parent-offspring pairs and 21 pairs with nonCLL in parents and/or in offspring. The median age 
of onset of disease was 13 years lower in the offspring than in the parents when comparing all 51 pairs (P  0.001). This difference 
was mainly caused by a significantly lower age at onset in offspring with parental nonCLL (P  0.001) where paternal disease was 
transferred especially to sons, while affected offspring to parents with CLL have the same age at debut of disease than their parents 
(P = 0.130) and a nearly equal transfer to sons and daughters. The low-malignant follicular small B-cell lymphoma was the predomi-
nant diagnosis within nonCLL. Anticipation is pointed out as one likely mechanism behind the lower age at onset of disease in off-
spring than in parents, even if a part of this difference is ascribed to a generally earlier diagnosis with modern technology in offspring 
than in parents.
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Introduction
Anticipation, which denotes a genetic pattern where 
the age at onset of disease decreases in successive gen-
erations with an increased severity and an increased 
number of affected family members,1 has been con-
sistently reported in chronic lymphocytic leukemia 
(CLL)  and  in  other  types  of  lymphoproliferative 
disorders (LPD).2–9 However, anticipation could not 
be verified by means of life-table methods and mar-
ginal survival methods in a population-based sample 
from Sweden, neither in CLL nor in other types of 
LPD.10,11
Anticipation is part of the pathogenesis of about 
twenty degenerative neurological disorders such as 
Huntington’s disease, familial Parkinson’s disease and 
the fragile X syndrome, where anticipation is caused 
by intergenerational increase of unstable nucleotide 
repeats in the disease-related genes, viz. expansion 
and genomic accumulation of tri-, tetra-, or penta-
nucleotide repeats in step with the progression of the 
disease down through the generations.12–14 Such unsta-
ble tri-nucleotide repeats have been reported in CLL 
related to variation in repeat length at certain FRA16A 
loci which may permit identification of susceptible 
  family members15 while other mechanisms than accu-
mulation of unstable CAG tri-nucleotide repeats were 
found to be involved in the generation of anticipation 
in familial CLL, e.g. accumulation of motif CCG.16 
The male predominance in CLL has so far not been 
related to larger accumulation of unstable nucleotide 
repeats in male than in female patients. However, an 
earlier onset of disease in children than in their par-
ents cannot be ascribed to anticipation alone, because 
bias from modern diagnostic techniques is likely if 
not inevitable: Easier access to the practitioner, effi-
cient health care programs which include automatic 
white blood cell counting and screening procedures 
for enlarged lymph nodes with standard procedure 
for diagnostic biopsy will evidently provide an earlier 
CLL diagnosis today than in former generations. Fur-
thermore, as stated in a study of familial Hodgkin’s 
disease, environmental factors such as simultaneous 
parent-offspring exposure to lymphotrope EBV virus 
could be related to anticipation.3
The  question  about  anticipation  in  CLL  is  cru-
cial  because  it  addresses  whether  or  not  unstable 
nucleotide  repeat  expansion  is  involved  in  the 
segregation of CLL and hence whether amplification 
or  suppression  in  and  outside  coding  repeats  with 
“gain- or loss-phenomenon”13,14,17 is relevant to CLL 
and its otherwise unknown mode of segregation. Gene-
alogical  interpretations  of  pedigrees  from  affected 
families suggest a non-Mendelian, epigenetic segre-
gation with a birth order effect and a male predomi-
nance of affected family members [for review see 18]. 
Pleiotropy, viz. a repertoire of gene-related pheno-
typic polytypes of other subsets of LPD than CLL, 
such  as  malignant  lymphomas,  multiple  myeloma 
and the other types of lymphocytic leukemias, is seen 
as a significant clustering of these disorders in all 
generations of affected families.19–27 The question is 
whether instability of the repeating nucleotides with 
manifestation in the form of anticipation as a pos-
sible error mechanism of the DNA reduplication can 
explain the meiotic drive behind such a pleiotropic 
and anticipative propagation of disease down through 
the generations.15,16
The  purpose  of  the  present  paper  is  to  discus-
sion whether genealogical interpretation of families 
with  CLL  by  means  of  independent  ascertainment 
  technique28 reveals signs of a different age at onset of 
disease in parents and in children? And if so, whether 
this  difference  is  equally  seen  in  affected  parent-
offspring pairs with CLL compared with other LPD 
diagnoses?
Material and Methods
Parent-offspring pairs
Thirty eight consecutive families from our data base 
on familial LPD were included. Fifty one affected 
parent-offspring pairs were identified, 30 CLL-CLL 
pairs and 21 pairs with nonCLL in parent and/or in 
offspring (Table 1). LPD denotes the entity of CLL 
and  nonCLL.  NonCLL  comprises  the  diagnoses 
reported in Table 2.
Families and pedigrees
Since 2002 all our CLL patients in Oslo and Copen-
hagen  have  been  interviewed  about  other  cases  of 
LPD  in  their  family.  Each  patient  has  also  been 
asked  about  the  number  and  positions  of  healthy 
members,  stillborns  and  extra-marital  individuals 
for a detailed description of the pedigree. Data were 
validated by crosschecking information in all cases Anticipation in families with cLL
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with the Cancer Registry in Denmark and Norway, 
respectively. Hospital records, and review of histo-
pathological and laboratory reports including infor-
mation  from  flowcytometry  and  cytogenetics  were 
crosschecked  when  available.  All  diagnoses  were 
based on standard criteria.29–34 CLL was confirmed by 
multicolour  flowcytometry  according  to  consensus 
guidelines.34 Karyotyping by interphase fluorescence 
in-situ hybridization (FISH) using standard protocols 
and commercially available probes, and assessment 
of the IgHV mutation status by DNA based sequenc-
ing were performed in all patients alive at the time of 
investigation. All patients investigated were of Scan-
dinavian origin.
Procurement of data was performed upon informed 
consent  and  that  the  study  was  approved  by  the 
  Scientific-Ethical Committees and the Data Protec-
tion Agencies in Norway and Denmark.
registration and inclusion
Since the affected parent-offspring pairs were inde-
pendently ascertained from the pedigrees,28 doublet 
counting of affected family members was inevitable 
in the following situations (Fig. 1): (a) one affected 
parent having more than one affected offspring, so that 
the same affected parent is counted for each affected 
sibs (n), when n  1. (b) affected family members 
in more than two generations, for example the com-
bination of an affected grand parent, parent and off-
spring, from which two pairs are ascertained (a grand 
  parent—ﾭparent pair and a parent—ﾭoffspring pair, viz. 
2 pairs with 4 patients) so that one parent is counted 
twice. (c) combinations of (a) and (b). Figure 1 shows 
that  the  present  material  comprises  12  such  dou-
blets, CLL 9 and nonCLL 3:follicular small B cell 
lymphoma  (FL)  2  and  lymphoplasmocytic  lym-
phoma (LPCL) 1. Thus, the 51 parent-offspring pairs 
(102 affected patients) comprise 90 affected family 
members of whom 12 are counted twice in order to 
include all ascertained parent offspring pairs.
Pairs  of  affected  aunt/uncle—ﾭniece/cousin  and 
sib-sib concordance were not included. Therefore, the 
material does not allow a calculation of the rates and 
total number of affected family members per family 
or per generation.
statistics
Comparison between parent and offspring was done 
by means of two-sided Wilcoxon Signed—ﾭRank Test. 
Significant difference was accepted when P  0.05.
Table . Parent-offspring with lymphoproliferative disease.
Affected pairs parents Offspring
cLL noncLL cLL noncLL
M p M p M p M p
cLL-cLL 17 7s
10d
cLL-cLL 13 9s
4d
cLL-noncLL 3 1s
2d
cLL-noncLL 4 2s
2d
noncLL-LPD 6 2s 2s
0d 2d
noncLL-LPD 8 6s 2s
0d 0d
Total 20 17 6 8 9s 15s 3s 4s
10d 4d 4d 2d
Total cLL 37 38
Total noncLL 14 13
LPD, lymphoproliferative disease in the sum of cLL and noncLL; For noncLL, see Table 2.
Abbreviations: M, matrilineal; P, patrilineal; d, daughter; s, son.Awan et al
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Results
Parent-offspring pairs
Out of a total of 51 parent-offspring pairs, there were 
37 (73%) pairs with parental CLL and 14 (27%) pairs 
with parental nonCLL (Table 1).
The most common parent-offspring combination 
was CLL-CLL, 30 pairs (69%) with a nearly equal 
distribution  of  matrilineal  and  patrilineal  CLL 
(17 vs. 13 cases) and a nearly equal number of affected 
sons and daughters (16 vs. 14) but a marked predomi-
nance of affected sons in patrilineal pairs (9 sons vs. 
4 daughters) (Table 1).
In  parental  nonCLL,  the  follicular  small  B  cell 
  lymphoma  stage  I-III  (FL)  and  FL  without  defi-
nite staging, denoted “FL  not  otherwise specified” 
(FLNOS),  was  most  common,  5  pairs  (10%)  seen 
together with a number of other nonCLL diagnoses 
in both parents and offspring (Table 2). Males were 
highly predominant among the offspring (12 affected 
sons  vs.  2  affected  daughters)  and  all  patrilineal 
combinations (8 of 14 pairs) were father—ﾭson pairs 
(Table 2).
Age at onset of disease
LPD, viz. pooled data from CLL and nonCLL, showed 
a significantly lower age at onset of disease in the off-
spring than in the parents, most pronounced in patrilin-
eal (P = 0.005) compared with matrilineal inheritance 
(P  =  0.015),  with  an  13  years  overall  difference 
between the median value of parents and offspring 
(Table 3).
Only pairs with parental nonCLL contributed to 
this difference while pairs with parental CLL do not 
(Tables 4 and 5).
Parental cLL
Table 4 shows that no significant difference in the age 
at onset was seen, neither when investigated accord-
ing  to  patrilineal  and  matrilinieal  inheritance,  nor 
according to the gender of offspring, sons vs. daugh-
ters.  All  subgroups  of  pairs  exhibited  a  generally 
lower age at debut of disease in the offspring than in 
the parents, but this difference was not statistically 
different (P  0.05).
A number of nonCLL diagnoses in offspring with 
parental CLL was recorded, n = 7 (Table 2) but no 
specific pattern in the segregation of nonCLL from 
the parents with CLL could be seen (Table 2).
Parental noncLL
In  remarkable  contrast  to  the  group  above,  pairs 
with parental nonCLL (Table 5) showed a signifi-
cantly lower age at onset of disease in the offspring 
than in the parents, also when the material is sorted 
out  according  to  matrilineal  vs.  patrilineal  inheri-
tance, or in subgroups according to offspring CLL 
vs. offspring nonCLL. Sons are predominant in the 
group of parental nonCLL (12 sons vs. 2 daughters) 
(Tables 1 and 2) and CLL is far the most commonly 
seen diagnosis among the 12 sons: CLL 8, nonCLL 4 
(Table 2).
We have been looking for a possible pattern in the 
pleiotropic repertoire of affected parents and offspring 
(Table  2).  FL  and  FLNOS  is  predominant  among 
the parents (FL and FLNOS 7 vs. all other types of 
Table . Specification of nonCLL in parent-offspring pairs.
Affected 
pairs
parents Offspring
M p Daughter son
cLL-noncLL
n = 3 cLL
cLL
cLL
Pre-B ALL
FL
WA
n = 4 cLL
cLL
cLL
cLL
igM MgUs
DLBcL
TLnOs
hL
noncLL-LPD
n = 6 MM
LPcL
TPLL
MM
DLBcL
FL
LPcL
FL
cLL
MM
cLL
hL
n = 8 DLBcL
FL
FLnOs
FLnOs
FL
FL
FL
DLBcL
hL
cLL
cLL
cLL
MM
cLL
cLL
cLL
Abbreviations: M, matrilineal; P, patrilineal, ALL, acute lymphoblastic 
leukemia; cLL, chronic lymphocytic leukemia; DLBcL, diffuse large B cell 
lymphoma; FL, follicular small B cell lymphoma hL, hodgkin's lymphoma, 
LPcL, lymphoplasmacytic lymphoma; MgUs, monoclonal gammopathy 
of  uncertain  significance;  MM,  multiple  myeloma;  NOS,  not  oterwise 
specified; TL, small T cell lymphoma NOS; TPLL, T cell prolymphocytic 
leukemia; W, Waldenström’s disease.Anticipation in families with cLL
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Figure . The independent ascertainment technique used in the present investigation for the identification of affected parent-offspring pairs caused dou-
ble counting of affected family members in situations with one affected parent and more affected sibs (2 families), and in situations with affected family 
members in more than two subsequent generations (3 families), and in combinations thereof (3 families). Thus, 9 cases of cLL and 3 cases of noncLL 
were counted twice.
Abbreviations: cLL, chronic lymphocytic leukemia; FL, follicular B cell lymphoma stage i–iii; hL, hodgkin′s lymphoma; LPcL, lymphoplasmacytic 
  lymphoma; MM, multiple myeloma; NOS, not otherwise specified; TL, small T cell lymphoma.
CLL - TLNOS 
CLL - CLL
Doublet: CLL (1) Doublet: CLL (1)
CLL - CLL
CLL - CLL
Doublet: FL (1)
CLL - FL
FL - HL
Doublets: FLNOS (1) and
FLNOS - MM
FLNOS - CLL
CLL - CLL
CLL (1)
Doublet: LPCL (1)
MM - LPCL
LPCL - FL
CLL - HL
Doublets: CLL (3)
CLL - CLL
CLL - CLL
CLL - CLL
One parent - two offspring pairs (n = 2)
Grad parent - parent - offspring combinations (n = 3)
CLL - CLL
CLL - CLL
Doublet: CLL (1)
CLL - CLL
CLL - CLL
CLL - CLL
Doublets: CLL (2)
Combined (n = 3)Awan et al
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  nonCLL  7),  especially  in  patrilineal  combinations 
(FL and FLNOS 6 vs. all other types of nonCLL 4) 
(Table 4).
Discussion
A different age at onset of disease between parent 
and offspring does not mean genetic anticipation as 
the only explanation. People of today see their doc-
tor earlier and for less than their parents and grand 
parents,  seemingly  healthy  people  are  checked  in 
public  health  care  programs  with  blood  screen-
ing, and medical progress has provided a faster and 
safe diagnostic process today so that also pre-stages 
of  malignant  disorders  such  as  MBL  (monoclonal 
B-lymphocytosis of uncertain significance which can 
be a sign of smouldering CLL) and MGUS (mono-
clonal  gammopathy  of  uncertain  significanse,  well 
known as a possible early manifestation of malignt 
B-lymphoproliferative disease) are diagnosed at an 
increasing scale today.35–37 We probably see this ten-
dency in the present material, as the median value of 
age at onset of disease in all parent-offspring combi-
nations investigated were lower in the offspring than 
in the parents. (Tables 3–5).
Table . Age at onset of lymphoproliferative disease in parent-offspring pairs.
Affected pairs Min I7% Max M p
LPD-LPD
Total
n = 51
parents
offspring
40
25
52–75
47–61
86
84
66
53
0.001
LPD-LPD
Matrilineal
n = 26
mothers
offspring
40
25
50–77
49–61
84
76
68
55
0.015
LPD-LPD
Patrilineal
n = 25
fathers
offspring
46
32
54–75
43–64
86
84
65
52
0.005
notes: Wilcoxon signed-rank test showing the 75% interquartile range (i 75%), median (M), minimum (min) and maximum (max) values, and the   
two-sided P value.
Table . Age at onset of disease in parent-offspring pairs with parental cLL.
Affected pairs Min I7% Max M p
cLL-cLL
Total
n = 30
parents
offspring
40
42
48–77
51–66
86
84
66
57
0.130
cLL-cLL
Matrilineal
n = 17
mothers
offspring
40
44
46–78
53–69
84
71
57
56
0.370
cLL-cLL
Patrilineal
n = 13
fathers
offspring
46
42
55–75
51–69
86
84
68
58
0.240
cLL-cLL
Female child
n = 14
parents
daughter
44
44
48–77
49–66
86
84
72
58
0.154
cLL-cLL
Male child
n = 16
parents
sons
40
42
46–75
51–69
81
75
65
56
0.215
cLL-noncLL
Total
n = 7
parents
offspring
48
32
54–71
48–64
78
76
65
57
0.110
notes: Wilcoxon signed-rank test showing the 75% interquartile range (l 75%), median (M), minimum (min) and maximum (max) values, and the   
two-sided P value.Anticipation in families with cLL
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However, a striking difference between CLL and 
nonCLL  is  disclosed,  since  only  parental  nonCLL 
  contributes to this difference (Table 5) while parental 
CLL does not (Table 4). In the group of parental nonCLL, 
the majority of pairs are father—ﾭson combinations, and 
all patrilineal pairs are father—ﾭson combinations (8 of 
14 pairs) without any father—ﾭdaughter combination. 
In 6 of the 8 father—ﾭson pairs, the offspring has CLL 
(Table 1).
The influence of bias or other systemic errors in 
the collection of data, including the influence of mod-
ern medical technology, will exert its action equally 
in the two groups parental CLL and parental nonCLL, 
and without doubt the difference in age at onset of 
disease between the two groups is real. Undetected 
low-grade LPD without clinical symptoms, for exam-
ple MGUS, MBL and sometimes silent stage A CLL 
will  cause  truncation  of  data,  but  equally  in  both 
groups, as also the LPD diagnoses to come in family 
members who are healthy at the time of investigation 
based on the fact that only dead family members have 
been observed long enough to ensure whether they 
have or have had LPD or not.
The difference in age at onset of disease between 
parental  CLL  and  parental  nonCLL  is  furthermore 
surprising because in CLL, the mean age at onset of 
disease is generally higher than the mean age at onset 
in most of the nonCLL diagnoses so that the age in 
CLL parents should be expected to be higher than the 
age in nonCLL offspring, but seven pairs of CLL-
nonCLL  combination  show  no  such  difference  in 
contrast to the pairs with parental nonCLL (Table 4). 
In spite of the low numbers, these observations focus 
attention  on  a  biological  mechanism  like  anticipa-
tion, and to interpret the extreme male predominance 
in offspring to parents with nonCLL as a sort of sex-
related inheritance, which is not seen in the offspring 
to parental CLL (Table 2). The male predominance in 
affected offspring to parental CLL is in accordance 
with recent findings that non-Hodgkin’s lymphoma 
confer a stronger familial association among men than 
among women.25 Such a different pattern in the segre-
gation of CLL and nonCLL can hardly be explained 
by  a  Mendelian  mechanism  but  calls  attention  to 
an epigenetic modality. Pregnancy related genomic 
imprinting with  a  birth order  effect has  been sug-
gested as one likely epigenetic mechanism in which 
selective DNA methylation and histone modifications 
of paternal genes, controlled by the pregnant mother, 
is the executive molecular mechanism.18,38–42
Without knowledge about the segregation of the 
CLL susceptibility genes and with the reservation that 
parts of the tumorigenesis in CLL depends on other 
genetic  factors  than  susceptibility,  e.g.  antigenic- 
and autoimmune drive, the findings from the present 
study indicate that the genetics of CLL and nonCLL 
is linked, and that a meiotic drive directs the suscep-
tibility especially in men towards a lower and lower 
Table . Age at onset of disease in parent-offspring pairs with parental noncLL.
Affected pairs Min I7% Max M p
noncLL-LPD
Total
n = 14
parents
offspring
48
25
55–74
38–49
78
61
68
46
0.001
noncLL-LPD
Matrilineal
n = 6
mothers
offspring
52
25
61–74
36–49
78
52
69
47
0.032
noncLL-LPD
Patrilineal
n = 8
fathers
offspring
48
36
54–75
38–60
75
61
67
43
0.008
noncLL-noncLL
n = 6
parents
offspring
52
25
61–75
36–52
78
60
69
49
0.031
noncLL-cLL
n = 8
parents
offspring
48
38
54–74
43–47
75
61
68
46
0.008
notes: Wilcoxon signed-rank test showing the 75% interquartile range (i 75%), median (M), minimum (min) and maximum (max) values, and the   
two-sided P value.Awan et al
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age  of  onset  of  CLL  from  nonCLL  predecessors. 
This is or mimics anticipation with regard to a lower 
age of onset. The other haft of anticipation related 
to an increased severity of disease down through the 
  generations cannot be statistically estimated in the 
present investigation because CLL was the only entry 
to study, but in accordance with anticipation, a single 
case of acute lymphoblastic leukemia, which is the 
most aggressive subset of LPD, was seen in a daugh-
ter to a mother with CLL (Table 2).
The present genealogical investigation based on 
independent  ascertainment  technique  found  a  sig-
nificant different age at onset of disease in nonCLL 
pairs, mean difference: 13 years between parents and 
children (Table 3). Genealogical studies of familial 
Hodgkin’s disease have showed 22 years between age 
at onset in parents and in children.43 These differences 
are in contrast to the findings from population based 
investigations based on data from Cancer Registries 
showing no anticipation.10,11 Most likely, the genea-
logical studies comprise all know cases of LPD in a 
given family, ensured from a meticulous crosscheck 
of all family members and a detailed family history 
so that the risk of incomplete ascertainment is elimi-
nated.28  Furthermore,  such  genealogical  investiga-
tions of pedigrees do not need a normal material for 
control in the same way as it is needed in population 
based studies. A normal material for such use must be 
roughly of the same period of time and from a similar 
environment which is certainly difficult for the obser-
vation window in question (from about 1900 to now) 
where a highly pronounced dynamic of the popula-
tion took place at the same time as the diagnostic cri-
teria for CLL and LPD were changed nearly every 
10th year since the fifties. Finally, a normal mate-
rial for comparison in population based studies will 
inevitably be contaminated with low-grade LPD such 
as undiagnosed cases of MGUS, MBL and stage A 
CLL without symptoms which is a matter of concern 
especially when to estimated rare disorders with low 
incidences.
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